GH Research Enterprise Value Multiple Over Time

GHRS Stock  USD 10.60  0.05  0.47%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out GH Research Performance and GH Research Correlation.
  
Enterprise Value Multiple is likely to drop to -5.15 in 2025.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GH Research. If investors know GHRS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GH Research listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.75)
Return On Assets
(0.15)
Return On Equity
(0.20)
The market value of GH Research PLC is measured differently than its book value, which is the value of GHRS that is recorded on the company's balance sheet. Investors also form their own opinion of GH Research's value that differs from its market value or its book value, called intrinsic value, which is GH Research's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GH Research's market value can be influenced by many factors that don't directly affect GH Research's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GH Research's value and its price as these two are different measures arrived at by different means. Investors typically determine if GH Research is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GH Research's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Enterprise Value Multiple Analysis

Compare GH Research PLC and related stocks such as Molecular Partners, MediciNova, and Anebulo Pharmaceuticals Enterprise Value Multiple Over Time
Select Fundamental
Price To Sales RatioPtb Ratio
Days Sales OutstandingBook Value Per Share
Free Cash Flow YieldInvested Capital
Operating Cash Flow Per ShareAverage Payables
Stock Based Compensation To RevenueCapex To Depreciation
Pb RatioEv To Sales
Free Cash Flow Per ShareInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Sales General And Administrative To RevenueAverage Inventory
Research And Ddevelopement To RevenueCapex To Revenue
Cash Per SharePocfratio
Interest CoveragePayout Ratio
Capex To Operating Cash FlowPfcf Ratio
Days Payables OutstandingNet Current Asset Value
Income QualityTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Ev To Free Cash FlowIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Dividend YieldRoic
Payables TurnoverRoe
Return On Tangible AssetsEarnings Yield
Receivables TurnoverShort Term Coverage Ratios
Price Earnings RatioOperating Cycle
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Capital Expenditure Coverage RatioPrice Cash Flow Ratio
Enterprise Value MultipleDebt Ratio
Cash Flow To Debt RatioPrice Sales Ratio
Net Profit MarginGross Profit Margin
Price Fair ValueReturn On Capital Employed
Fixed Asset TurnoverReturn On Assets
Asset TurnoverReturn On Equity
2010201120122013201420152016201720182019202020212022202320242025
MOLN43.635843.635843.635843.6358(107)643(20.3659)(16.8974)(7.9868)(8.9608)(6.5833)(8.0238)0.995(0.8246)(1.4859)(1.41)
MNOV(0.2717)(0.6272)(2.2332)(9.58)(8.7386)(9.659)(16.1726)(15.3354)(19.3361)(16.2415)(12.274)(5.7842)(5.933)(2.3063)(2.65)(2.78)
ANEB(955)(955)(955)(955)(955)(955)(955)(955)(955)(955)(4.6039)19.2 K(4.0461)(8.2119)(7.39)(7.02)
CSBR39.45(2.9357)(1.3723)(9.088)(4.1725)(3.0487)(3.7446)(47.1173)114(118)39945.5744(31.0744)(13.9529)(12.56)(11.93)
MLYS(21.1473)(21.1473)(21.1473)(21.1473)(21.1473)(21.1473)(21.1473)(21.1473)(21.1473)(21.1473)(21.1473)(21.1473)(21.1473)(3.0938)(2.5126)(2.64)
JANX(279)(279)(279)(279)(279)(279)(279)(279)(279)(279)(215)(23.7183)(7.8496)(6.7249)(24.9909)(26.24)
RZLT(5.3212)(5.3212)(5.3212)(3.5973)(3.1859)(1.4665)(2.2018)(0.9547)(0.2372)(0.8465)(3.6204)2.1861(1.7079)(2.2455)(2.02)(2.12)
PMVP(67.2911)(67.2911)(67.2911)(67.2911)(67.2911)(67.2911)(67.2911)(67.2911)(67.2911)(65.0904)(69.1099)(15.2003)(3.9407)(1.5775)(0.447)(0.47)
PHVS(185)(185)(185)(185)(185)(185)(185)(185)(185)(13.1204)(25.0157)(3.2509)(2.2113)(6.022)(5.42)(5.69)
PEPG(228)(228)(228)(228)(228)(228)(228)(228)(228)(228)(158)(5.7833)(2.3571)(1.2101)(1.09)(1.14)
GLUE(121)(121)(121)(121)(121)(121)(121)(121)(121)(121)(34.8721)(8.5398)(3.5169)(1.5197)(1.37)(1.44)
DSGN(8.1 K)(8.1 K)(8.1 K)(8.1 K)(8.1 K)(8.1 K)(8.1 K)(8.1 K)(8.1 K)(8.1 K)(135)(19.2885)(8.7322)(1.9632)(5.2597)(5.52)
HOWL(47.4596)(47.4596)(47.4596)(47.4596)(47.4596)(47.4596)(47.4596)(47.4596)(47.4596)(47.4596)(26.0441)(3.7246)1.0811(1.6995)0.57910.61
IKNA(29.4652)(29.4652)(29.4652)(29.4652)(29.4652)(29.4652)(29.4652)(29.4652)(29.4652)(62.6897)(22.274)(6.7243)(0.5992)0.3621(0.8016)(0.84)
STOK(60.3052)(60.3052)(60.3052)(60.3052)(60.3052)(60.3052)(60.3052)(60.3052)(39.4523)(8.1322)(35.5091)(8.8302)(2.4105)(0.3743)(0.34)(0.35)
RCUS(20.8839)(20.8839)(20.8839)(20.8839)(20.8839)(20.8839)(20.8839)(12.2948)(5.8946)(4.7417)(10.6705)44.7917(5.6118)(4.5845)(4.6081)(4.38)
CGEM(21.2216)(21.2216)(21.2216)(21.2216)(21.2216)(21.2216)(21.2216)(21.2216)(21.2216)(55.7801)(18.8039)(3.7196)(0.4521)(1.7238)(1.55)(1.63)
ANNX(35.8712)(35.8712)(35.8712)(35.8712)(35.8712)(35.8712)(35.8712)(35.8712)(14.2794)(19.8244)(2.4841)(3.1111)(1.2231)(1.0581)(4.4418)(4.66)
GPCR(242)(242)(242)(242)(242)(242)(242)(242)(242)(242)(242)(101)(71.0465)(57.237)(7.9756)(8.37)
RLAY7.00167.00167.00167.00167.00167.00167.00167.00167.0016(1.637)(25.8014)(8.9408)(2.3975)(3.3657)(1.3488)(1.42)

GH Research PLC and related stocks such as Molecular Partners, MediciNova, and Anebulo Pharmaceuticals Enterprise Value Multiple description

My Equities

My Current Equities and Potential Positions

GH Research PLC
GHRS
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationIreland
ExchangeNASDAQ Exchange
USD 10.6

Additional Tools for GHRS Stock Analysis

When running GH Research's price analysis, check to measure GH Research's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GH Research is operating at the current time. Most of GH Research's value examination focuses on studying past and present price action to predict the probability of GH Research's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GH Research's price. Additionally, you may evaluate how the addition of GH Research to your portfolios can decrease your overall portfolio volatility.